Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE
OP-1250-301
Phase 3 small_molecule active
Quick answer
Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE for ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy is a Phase 3 program (small_molecule) at Olema Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Olema Pharmaceuticals
- Indication
- ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active